Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 10/20 | 0.43 |
| ▸ | PRNP | P04156 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 2/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2375560 | 1.00 | PTGIR (0.43) | PTGIRPRNPHTR2CSLC6A4ACACB | |
| SCHEMBL2375204 | 0.90 | PTGIR (0.43) | PTGIRPRNPHTR2CSLC6A4MAPT | |
| SCHEMBL2375209 | 0.90 | PTGIR (0.43) | PTGIRPRNPHTR2CSLC6A4MAPT | |
| SCHEMBL2377141 | 0.90 | PTGIR (0.52) | PTGIRPRNP | |
| SCHEMBL2377142 | 0.90 | PTGIR (0.52) | PTGIRPRNP | |
| SCHEMBL2377644 | 0.90 | PRNP (0.42) | PTGIRPRNPHTR2CSLC6A4ACACB | |
| SCHEMBL2377645 | 0.90 | PRNP (0.42) | PTGIRPRNPHTR2CSLC6A4ACACB | |
| SCHEMBL21314892 | 0.90 | PRNP (0.42) | PTGIRPRNPHTR2CSLC6A4ACACB | |
| SCHEMBL2374035 | 0.89 | PTGIR (0.45) | PTGIRPRNPHTR2CSLC6A4ACACB | |
| SCHEMBL2374031 | 0.89 | PTGIR (0.45) | PTGIRPRNPHTR2CSLC6A4ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3342767-B1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190270731-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-05 | — | — | US | disclosed |
| EP-3342767-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180030039-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-9663500-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150191455-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-9012478-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140171469-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | PTGIR 1/4885PRNP 2348/4885HTR2C 2420/4885 |
| US-20150191455-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | PTGIR 1/4885PRNP 2348/4885HTR2C 2420/4885 |
| US-20140171469-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | PTGIR 1/4885PRNP 2348/4885HTR2C 2420/4885 |
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | PTGIR, PTGIS, PTGER1 | PTGIR 1/4885PRNP 2348/4885HTR2C 2420/4885 |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | PTGIR 1/4885PRNP 2348/4885HTR2C 2420/4885 |
| US-20180030039-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | PTGIR 1/4885PRNP 2348/4885HTR2C 2420/4885 |
| US-20190270731-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | PTGIR 1/4885PRNP 2348/4885HTR2C 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.